| B cells are associated with survival and immunotherapy response in sarcoma F Petitprez, A de Reyniès, EZ Keung, TWW Chen, CM Sun, J Calderaro, ... Nature 577 (7791), 556-560, 2020 | 1321 | 2020 |
| Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial HA Tawbi, M Burgess, V Bolejack, BA Van Tine, SM Schuetze, J Hu, ... The Lancet Oncology 18 (11), 1493-1501, 2017 | 1112 | 2017 |
| Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for … RG Maki, JK Wathen, SR Patel, DA Priebat, SH Okuno, B Samuels, ... J clin oncol 25 (19), 2755-2763, 2007 | 842 | 2007 |
| NCCN task force report: oral chemotherapy SN Weingart, E Brown, PB Bach, K Eng, SA Johnson, TM Kuzel, ... Journal of the National Comprehensive Cancer Network 6 (S3), S-1-S-14, 2008 | 587 | 2008 |
| R1507, a monoclonal antibody to the insulin-like growth factor 1 receptor, in patients with recurrent or refractory Ewing sarcoma family of tumors: results of a phase II … AS Pappo, SR Patel, J Crowley, DK Reinke, KP Kuenkele, SP Chawla, ... Journal of Clinical Oncology 29 (34), 4541, 2011 | 362 | 2011 |
| Cancer-and chemotherapy-induced anemia GM Rodgers, PS Becker, M Blinder, D Cella, A Chanan-Khan, C Cleeland, ... Journal of the National Comprehensive Cancer Network 10 (5), 628-653, 2012 | 281 | 2012 |
| Doxorubicin plus evofosfamide versus doxorubicin alone in locally advanced, unresectable or metastatic soft-tissue sarcoma (TH CR-406/SARC021): an international, multicentre … WD Tap, Z Papai, BA Van Tine, S Attia, KN Ganjoo, RL Jones, S Schuetze, ... The lancet oncology 18 (8), 1089-1103, 2017 | 265 | 2017 |
| Phase II multicenter trial of imatinib in 10 histologic subtypes of sarcoma using a bayesian hierarchical statistical model R Chugh, JK Wathen, RG Maki, RS Benjamin, SR Patel, PA Myers, ... Journal of clinical oncology 27 (19), 3148-3153, 2009 | 245 | 2009 |
| Randomized double-blind phase II study of regorafenib in patients with metastatic osteosarcoma LE Davis, V Bolejack, CW Ryan, KN Ganjoo, ET Loggers, S Chawla, ... Journal of Clinical Oncology 37 (16), 1424, 2019 | 207 | 2019 |
| NCCN biosimilars white paper: regulatory, scientific, and patient safety perspectives AD Zelenetz, I Ahmed, EL Braud, JD Cross, N Davenport-Ennis, ... Journal of the National Comprehensive Cancer Network 9 (Suppl_4), S-1-S-22, 2011 | 195 | 2011 |
| Toward a drug development path that targets metastatic progression in osteosarcoma C Khanna, TM Fan, R Gorlick, LJ Helman, ES Kleinerman, PC Adamson, ... Clinical Cancer Research 20 (16), 4200-4209, 2014 | 155 | 2014 |
| Correlative analyses of the SARC028 trial reveal an association between sarcoma-associated immune infiltrate and response to pembrolizumab EZ Keung, M Burgess, R Salazar, ER Parra, J Rodrigues-Canales, ... Clinical Cancer Research 26 (6), 1258-1266, 2020 | 135 | 2020 |
| Phase II study of sequential gemcitabine followed by docetaxel for recurrent Ewing sarcoma, osteosarcoma, or unresectable or locally recurrent chondrosarcoma: results of … E Fox, S Patel, JK Wathen, S Schuetze, S Chawla, D Harmon, D Reinke, ... The oncologist 17 (3), 321-e329, 2012 | 127 | 2012 |
| Phase 2 study of dasatinib in patients with alveolar soft part sarcoma, chondrosarcoma, chordoma, epithelioid sarcoma, or solitary fibrous tumor SM Schuetze, V Bolejack, E Choy, KN Ganjoo, AP Staddon, WA Chow, ... Cancer 123 (1), 90-97, 2017 | 117 | 2017 |
| SARC009: phase 2 study of dasatinib in patients with previously treated, high‐grade, advanced sarcoma SM Schuetze, JK Wathen, DR Lucas, E Choy, BL Samuels, AP Staddon, ... Cancer 122 (6), 868-874, 2016 | 99 | 2016 |
| Clinical activity of pembrolizumab (P) in undifferentiated pleomorphic sarcoma (UPS) and dedifferentiated/pleomorphic liposarcoma (LPS): Final results of SARC028 expansion cohorts. MA Burgess, V Bolejack, S Schuetze, BA Van Tine, S Attia, RF Riedel, ... Journal of Clinical Oncology 37 (15_suppl), 11015-11015, 2019 | 84 | 2019 |
| SARC006: phase II trial of chemotherapy in sporadic and neurofibromatosis type 1 associated chemotherapy-naive malignant peripheral nerve sheath tumors CS Higham, SM Steinberg, E Dombi, A Perry, LJ Helman, SM Schuetze, ... Sarcoma 2017, 2017 | 83 | 2017 |
| Safety and efficacy of PD-1 blockade using pembrolizumab in patients with advanced soft tissue (STS) and bone sarcomas (BS): Results of SARC028—A multicenter phase II study. HAH Tawbi, MA Burgess, J Crowley, BA Van Tine, J Hu, S Schuetze, ... Journal of Clinical Oncology 34 (15_suppl), 11006-11006, 2016 | 75 | 2016 |
| Cancer-and chemotherapy-induced anemia GM Rodgers 3rd, PS Becker, CL Bennett, D Cella, A Chanan-Khan, ... Journal of the National Comprehensive Cancer Network: JNCCN 6 (6), 536-564, 2008 | 63 | 2008 |
| Targeting sporadic and neurofibromatosis type 1 (NF1) related refractory malignant peripheral nerve sheath tumors (MPNST) in a phase II study of everolimus in combination with … BC Widemann, Y Lu, D Reinke, SH Okuno, CF Meyer, GM Cote, R Chugh, ... Sarcoma 2019, 1-8, 2019 | 48 | 2019 |
